Inflammation as a factor of the pathogenesis of insulin resistance and type 2 diabetes

Terapevticheskii Arkhiv

Volumn 81, Issue 10, 2009, Pages 74-80

  Schwarz, V ^a  

^a Rehabilitationsklinik Bad Colberg ^*  (Germany)

Author keywords

Adipose tissue; Inflammation; Insulin resistance; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; HYPOGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; TIME;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TIME FACTORS;

EID: 75549083740     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Shoelson S. E., Lee J., Goldfine A. B. Inflammation and insulin resistance. J. Clin. Invest. 2006; 116: 1793-1801. (Pubitemid 44033299)
2. Tilg H., Moschen A. R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 2008; 14 (3-4): 222-231. (Pubitemid 351481853)
3. Cave M. C, Hurt R. T., Frazier T. H. et al. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr. Clin. Pract. 2008; 23 (1): 16-34. (Pubitemid 351438965)
4. Ebstein W. Zur therapie des Diabetes mellitus, insbesondere uber die Anwendung des salicylsauren Natron bei demselben. Berliner Klinische Wochenschrift. 1876; 13: 337-340.
5. Williamson R. T. On the treatment of glucosuria and diabetes mellitus with sodium salicylate. Br. Med. J. 1901; 1: 760-762.
6. Reid J., Macdougall A. I., Andrews M. M. On the efficacy of salicylate in treating diabetes mellitus. Br. Med. J. 1957; 2: 1071-1074.
7. Baron S. H. Salicylates as hypoglycemic agents. Diabet. Care 1982; 5: 64-71. (Pubitemid 12212125)
8. Yuan M. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKB. Science 2001; 293:1673-1677. (Pubitemid 32807849)
9. Hotamisligil G. S., Shargill N. S., Spiegelman B. M. Adipose expression of tumor necrosis factor-: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91. (Pubitemid 23036092)
10. Cavalot F, Massucco R, Perm P. et al. White blood cell counts is positively correlated with albumin excretion rate in subjects with type 2 diabetes. Diabet. Care 2002; 25 (12): 2354-2355.
11. Veronelli A., Laneri M., Ranieri R. et al. White blood cells in obesity and diabetes: effects ofr weight loss and normalisation of glucose metabolism. Diabet. Care 2004; 27 (10): 2501-2502. (Pubitemid 39281411)
12. Chen L. K., Lin M. H., Chen Z. J. et al. Association of insulin resistance and hematologic parameters: study of a middle-aged and elderly Chinese population in Taiwan. J. Chin. Med. Assoc. 2006; 69 (6): 248-253.
13. Zuiet M. A., Puchau B., Navarro C. et al. Inflammatory bi-omarkers: the link between obesity and associated pathologies. Nutr. Hosp. 2007; 22 (5): 511-527. (Pubitemid 350014429)
14. Han T. S., Sattar N., Williams K. et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City diabetes study. Diabet. Care 2002; 25: 2016-2021. (Pubitemid 41071061)
15. Takebayashi K., Suetsugu M., Matsutomo R. et al. Correlation of high-sensitivity C-reactive protein and plasma fibrinogen with individual complications in patients with type 2 diabetes. South. Med. J. 2006; 99: 23-27.
16. Steensberg A. The role of IL-6 in exercise-induced immune changes and metabolism. Exerc. Immunol. Rev. 2003; 9: 40-47.
17. Pang S., Le Y. Role of resistin in inflammation and inflammation-related diseases. Cell. Mol. Immunol. 2006; 3: 29-34.
18. Xu W., Yu L., Zhou W., Luo M. Resistin increases lipid accumulation and CD36 expression in human macrophages. Bio-chem. Biophys. Res. Commun. 2006; 351: 376-382. (Pubitemid 44666699)
19. Jung H. S., Park K. H., Cho Y. M. et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc. Res. 2006; 69: 76-85. (Pubitemid 41814813)
20. Weisberg S. P., McCann D., Desai M. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003; 112: 1796-1808. (Pubitemid 38063703)
21. Curat C. A., Wegner V., Sengenes C. et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747. (Pubitemid 43357549)
22. Arkan M. C, Havener A. L., Greten F. R. et al. IKK-beta links inflammation of obesity-related insulin resistance. Nat. Med. 2005; 11: 191-198. (Pubitemid 40321355)
23. Weisberg S. P., Hunter D., Huber R. et al. CCR2 modulates inflammatory and metabolic effects of high fat feeding. J. Clin Invest. 2006; 116: 115-124. (Pubitemid 43121796)
24. Fernandez-Real J. M., Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr. Rev. 2003; 24-278-301. (Pubitemid 36724371)
25. Hirosumi J. et al. A central role for JNK in obesity and in-suline resistance. Nature 2002; 420: 333-336. (Pubitemid 35398190)
26. Cat D. et al. Local and systemic insulin resistance resulting from hepatic activation of LKK and NF-kB. Nat. Med. 2005-11: 183-190.
27. Fantuzzi G., Mazzone T. Adipose tissue and atherosclerosis: Exploring the connection. Arterioscler. Thromb. Vase. Biol 2007; 27: 996-1003. (Pubitemid 46641984)
28. Griffin M. E. et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signalling cascade. Diabetes 1999; 48: 1270-1274. (Pubitemid 29241025)
29. Itani S. I., Ruderman N. B., Schmieder F. et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002; 51: 2005-2011. (Pubitemid 34729001)
30. De Alvaro C, Teruel T., Hernandez R-, Lorenzo M. Tumor necrosis factor alpha produced insulin resistance in sceletal muscle by activation of inhibitor kappaBkinase in ap38 MARK-deppendent manner. J. Biol. Chem. 2004; 279: 17070-17078. (Pubitemid 38560462)
31. Granner D. K., O'Brien R. M. Molecular physiology and genetics of NIDDM. Diabet. Care 1992; 15: 369-395.
32. Ruan H., Lodisch H. F. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis faktor. Cytokine Growth Factor Rev. 2003; 14: 447-455. (Pubitemid 37099456)
33. Ruan H, Miles P. D., Ladd C. M. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-a: implications for insulin resistence. Diabetes 2002; 51: 3176-3188. (Pubitemid 35246963)
34. Judkin J. S. Inflammation, obesity, and the metabolic syndrome. Horm. Metab. Res. 2007; 39 (10): 707-709.
35. Boden G, Cheung P., Stein T. P. et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am. J. Physiol. Endocrinol. Mctab. 2002; 283 (1): E12-E19. (Pubitemid 34686662)
36. Kim J. K, Fillmore J. J., Sunshine M. J. et al. PKC-theta knockout mice are protected from fat-induced insulin resistance. J. Clin. Invest. 2004; 114 (6): 823-827. (Pubitemid 39578741)
37. Gao Z, Zhang X., Zuberi A. et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol. Endocrinol. 2004; 18 (8): 2024-2034. (Pubitemid 39006506)
38. Weisberg S. P. et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006; 116: 115-124. (Pubitemid 43121796)
39. Geffken D. F., Gushman M., Burke G. L. et al. Association between physical activity and markers of inflammation in a healthy elderly population. Am. J. Epidemiol. 2001; 153: 242-250. (Pubitemid 32958648)
40. Abramson J. L., Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged older US adults. Arch. Intern. Med. 2002; 162: 1286-1292. (Pubitemid 34595035)
41. Fallon K. E., Fallon S. K., Boston T. The acute phase response and exercise: court and field sports. Br. J. Sports Med. 2001; 35: 170-173. (Pubitemid 32973432)
42. Starkie R., Ostrowski S. R., Jauffred S. et al. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J. 2003; 17: 884-886.
43. Tsukui S., Kanda T., Nara M. et al. Moderate-intensity regular exercise decrease serum tumor necrose factor-alpha and HdFlc levels in healthy women. Int. J. Obes. Relat. Metab. Disord. 2000; 24: 1207-1211.
44. Nicklas B. J., Ambrosius W., Messier S. P. et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am. J. Clin. Nu-tr. 2004; 79: 544-551. (Pubitemid 41103895)
45. Esposito K, Pontillo A., Di Palo C. et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J. A. M. A. 2003; 289: 1799-1804. (Pubitemid 37430249)
46. De Mello V. D., Kolehmainen M., Schwab U. et al. Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. Metabolism 2008; 57 (2): 192-199.
47. Vendrell I, Broch M., Vilarassa N. et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationship in obesity. Obes. Res. 2004; 12: 962-971.
48. Laimer M., Ebenbichler C. F, Kaser S. et al. Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int. J. Obest. Relat. Metab. Disord. 2002; 26: 659-662. (Pubitemid 34499286)
49. Klein S., Fontana L., Young V. L. et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 2004; 350: 2549-2557. (Pubitemid 38758542)
50. Simpson R. W., Shaw J. E., Zimmer P. Z. The prevention of type diabetes - lifestyle change or pharmacotherapy? A challenge for the 21B century. Diabet. Res. Clin. Pract. 2003; 59 (3): 165-180. (Pubitemid 36183300)
51. Storlien L. H., Kraegen E. W., Chisholm D. J. et al. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 1987; 237: 885-888. (Pubitemid 17128276)
52. Geusens P., Wouters C, Nijs J. et al. Long term effect of ome-ga-3 fatty acid supplementation in active rheumatoid arthritis. A 12 month, double blind, controlled study. Arthr. and Rheum. 1994; 37: 824-829. (Pubitemid 24184532)
53. Beluzzi A., Brlgnola C, Campieri M. et al. Effect on enteric-coated fish-oil preparation on relapses in Crohn's disease. N. Engl. J. Med. 1996; 334: 1557-1560. (Pubitemid 26177482)
54. Rallidis L. S., Paschos G., Liakos G. K. et al. Dietary a-lino-lenic acid and decreases C-reactive protein, serum amyloid A and interleukin 6 in dyslipidaemic patients. Atherosclerosis 2003; 167: 237-242. (Pubitemid 36773523)
55. Trebble T., Arden N. K., Stroud M. A. et al. Inhibition of tumor necrosis factor alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Br. J Nutr. 2003; 90: 405-412. (Pubitemid 36992542)
56. TodoricJ., LofflerM., HuberJ. et al. Adipose tissue inflammation incuded by high-fat diet in obese diabetic moce is prevented by n-3 polyunsaturatcd fattv acids. Diabetologia 2006; 112: 239-254
57. Coreyy E. J., Shih C, Cashman J. R. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc. Natl. Acad. Sci. USA 1983; 80: 3581-3584. (Pubitemid 13063121)
58. Lee T. H., Mencia-Huerta J. M., Shih C. et al. Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J. Clin. Invest. 1984; 74: 1922-1933. (Pubitemid 15197332)
59. Hughes D. A. In vitro and in vivo effects of n-3 polyunsaturated fatty acids on human monocyte function. Proc. Nutr. Soc. 1998; 57: 521-525. (Pubitemid 128737122)
60. Bannenberg G. L., Chiang N., Ariel A. et al. Molecular circuits of resolution: formation and actions of resolvins and pro-tectins. J. Immunol. 2005; 174: 4345-4355. (Pubitemid 40396017)
61. Xu H. E., Lambert M. H., Montana V. G. et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 1999; 3: 397-403. (Pubitemid 29290680)
62. Lee C. H., Chawla A., Urbiztondo N. et al. Transcriptional repression of atherogenic inflammation: modulation by PPAR. Science 2003; 302: 453-457. (Pubitemid 37296272)
63. Neschen S., Morino K., Rossbacher J. C. et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-dependent mechanism in mice. Diabetes 2006; 55: 924-928. (Pubitemid 44100165)
64. Yki-Jarvinen H., Thiazolidinediones. N. Engl. J. Med. 2004; 351: 1106-1118.
65. Ialenti A. et al. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. Mol. Pharmacol. 2005; 67: 1620-1628. (Pubitemid 40594161)
66. Glass C. K., Ogawa S. Combinatorial roles of nuclear receptors in inflammational immunity. Nat. Rev. Immunol. 2006; 6: 44-55. (Pubitemid 43279752)
67. Castrillo A., Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell. Dev. Biol. 2004; 20: 455-480. (Pubitemid 39488646)
68. Goldstein B. J., Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. 2004; 89: 2563-2568. (Pubitemid 38766332)
69. Xiang A. H. et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517-522. (Pubitemid 43343284)
70. Meisner F. et al. Effect of pioglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: date from randomized placebo-controlled trial. Arterioscler. Thromb. Vase. Biol. 2006; 26: 845-850. (Pubitemid 43732161)
71. Bullkao C, Ribeiro-Filho F. F, Sanudo A. et al. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am. J. Car-diovasc. Drugs 2007; 7: 219-224. (Pubitemid 47047989)
72. Orio F., Manguso F., Di Biase S. et al. Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur. J. Endjcrinol. 2007; 157: 69-73. (Pubitemid 47162568)
73. Ersoy C, Kiyici S., Budak F. et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabet. Res. Clin. Pract. 2008; 3: 256-265.
74. Hannori Y., Suzuki K., Hattori S. et al. Metformin inhibits cy-tokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006; 47: 1183-1188. (Pubitemid 44289177)
75. Akbar D. H. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine 2003; 20: 215-218. (Pubitemid 36571021)
76. Yin W. H., Jen H. I., Chen L. W. et al. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment in plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabet. Metab. 2006; 32: 229-235. (Pubitemid 43966746)
77. Koshiba K., Nomura M., Nakaya Y., Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J. Med. Invest. 2006; 53: 87-94.
78. Hanefeld M Marx N., Pfutzner A. et al. Anti-inflammatory effects ot pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J. Am. Coll. Cardiol. 2007; 49: 290-297. (Pubitemid 46110954)
79. Gomez-Garcia A, Martinez T. G., Ortega-Pierres L. E. et al. Kosuyastatin and metformin decrease inflammation and oxidartive stress in patients with hypertension and dyslipidemia. Rev. Esp. Cardiol. 2007; 60: 1242-1249. (Pubitemid 350294323)
80. Kastelein J. P., Akdim F., Stroes E. S. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 2008; 358 (14): 1431-1443. (Pubitemid 351482735)
81. Barbuio R, Miianski M., Bertolo M. B. et al. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J. Endocrinol. 2007; 194: 539-550. (Pubitemid 47471222)
82. Bernstein L. E., Berry J., Kim S. et al. Effects of etanercept in patients with the metabolic syndrome. Arch. Intern. Med. 2006; 166: 902-908.
83. Paquot N., Castillo M. J., Lefebvre P. J. et al. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. 2000; 85: 1316-1319. (Pubitemid 32269392)
84. Dominguez H., Storgaard H., Rask-Madsen C. et al. Metabolic and vascular effects of tumor necrosis factor-alpha blocade with etanercept in obese patients with type 2 diabetes. J. Vase. Res. 2005; 42: 517-525. (Pubitemid 41527607)
85. Rosenvinge A., Krogh-Madsen R., Baslund B. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand. J. Rheumatol. 2007; 36: 91-96. (Pubitemid 46685768)
86. Yuan M., Konstantinopoulos N., Lee J. et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-1677. (Pubitemid 32807849)
87. Hundal R. S., Petersen K. E, Mayerson A. B. et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 2002; 109: 1321-1326. (Pubitemid 34546896)
88. Yin M. J., Yamamoto Y., Gaynor R. B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77-80. (Pubitemid 28520452)
89. Somm Cettour-Rose P., Aensio C. et al. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 2006; 49: 387-393.
90. Larsen C. M., Faulenboch M., Vaag A. et al. Interleukin-l-re-ceptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007; 356: 1517-1526. (Pubitemid 46588416)
91. Bogdanski P., Pupek-Musialik D., Dytfeld J. et al. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. Int. J. Clin. Pharmacol. Ther. 2007; 45: 563-567. (Pubitemid 47527456)
92. Dandona P., Chaudhuri A., Mohanty P., Ghanim H. Anti-inflammatory effects of insulin. Curr. Opin. Clin. Nutr. Metab. Care 2007; 10: 511-517. (Pubitemid 46934123)